





INSTITUTION PARTNERS



MEDIA PARTNERS




PharmaManufacturing.com



Report and Survey of Biopharmaceutical Manufacturing Capacity and Production

A Study of Biotherapeutic Developers and Contract Manufacturing Organizations



APRIL 2016

13th Annual

Report and Survey of Biopharmaceutical Manufacturing Capacity and Production

*A Study of Biotherapeutic Developers and Contract
Manufacturing Organizations*

April 2016



BioPlan Associates, Inc.
2275 Research Blvd., Suite 500
Rockville, MD 20850 USA
301.921.5979
www.bioplanassociates.com

Copyright ©2016 by BioPlan Associates, Inc.

All rights reserved. Unauthorized reproduction strictly prohibited.

13th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production

*A Study of Biotherapeutic Developers and Contract
Manufacturing Organizations*

April 2016

BioPlan Associates, Inc.
2275 Research Blvd, Suite 500
Rockville MD 20850
301-921-5979
www.bioplanassociates.com

Copyright © 2016 by BioPlan Associates, Inc.

All rights reserved, including the right of reproduction in whole or in part in any form. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the written permission of the publisher.

For information on special discounts or permissions contact
BioPlan Associates, Inc. at 301-921-5979, or info@bioplanassociates.com

Managing Editor: Eric S. Langer
Project Director: Donnie E. Gillespie
Assistant Editor: Ronald A. Rader
Layout and Cover Design: ES Design

ISBN 978-1934-106-28-0

COVER1: Automated Allegro systems for single use downstream operations.
© Pall Corporation, used with permission.

ACKNOWLEDGMENT

We wish to recognize our sponsoring institutions, and our media sponsors. Their efforts in assuring the cooperation and participation in the survey of their respective memberships helped guarantee the large group of survey participants to ensure data accuracy.

Our ***Institution Partners***, all of whom contributed their time and effort to ensure the broad, international coverage of this project, include:

- AusBiotech (Malvern, Victoria, Australia)
- ABO China (Beijing, China)
- Beijing Pharma and Biotech Center (Beijing, China)
- BIO (Biotechnology Industry Organization, Washington, D.C.)
- Bio-Process Systems Alliances/SOCMA (BPSA) (Washington, D.C.)
- BioMaryland (Rockville, MD)
- California Life Sciences Association (CLSA) (San Francisco, CA)
- Colorado BioScience Association (Denver, CO)
- KTN (Knowledge Transfer Network) (London, United Kingdom)
- D2L Pharma (Bangalore, India)
- EuropaBio (Brussels, Belgium)
- Massachusetts Biotechnology Council (Cambridge, MA)
- Massachusetts Life Sciences Center (Waltham, MA)
- MichBio (Ann Arbor, MI)
- North Carolina BioSciences Organization (Research Triangle Park, NC)
- North Carolina Biotechnology Center (Research Triangle Park, NC)
- Pharma & Biopharma Outsourcing Association (PBOA) (Ringwood, NJ)
- Washington Biotechnology & Biomedical Association (WBBA) (Seattle, WA)

To ensure global coverage for this project, we again invited major ***Media Sponsors*** to support our outreach to biopharmaceutical decision-makers. Our media sponsors, who helped ensure broad and representative coverage of industry participation, include:

- American Pharmaceutical Review (Fishers, IN)
- BioPharm International (Iselin, NJ)
- BioProcess International, (Westborough, MA)
- BioProcessing Journal (Winthrop, MA)
- Contract Pharma, (Ramsey, NJ)
- Genetic Engineering and Biotechnology News (New Rochelle, NY)
- Life Science Leader (Sewickley, PA)
- Pharma IQ (London, United Kingdom)
- Pharmaceutical Manufacturing (Schaumburg, IL)
- Pharmaceutical Outsourcing (Fishers, IN)
- Pharmaceutical Processing (Rockaway, NJ)
- Pharmaceutical Technology (Iselin, NJ)
- Pharmaceutical Technology Europe (Iselin, NJ)

The early participation of our authors and sponsors in evaluating the areas and trends to be surveyed this year ensured the project was designed to cover the most relevant issues in biopharmaceutical manufacturing today. As always, their continued support was critical to the success of the project.

Eric S. Langer
Editor

ABOUT BIOPLAN ASSOCIATES, INC.

BioPlan Associates, Inc. is a biotechnology and life sciences market analysis, research, and publishing organization. We have managed biotechnology, biopharmaceutical, diagnostic, and life sciences research projects for companies of all sizes for almost 30 years. Our extensive market analysis, research and management project experience covers biotechnology and biopharmaceutical manufacturing, vaccine and therapeutic development, contract research services, diagnostics, devices, biotechnology supply, physician office labs and hospital laboratory environments.

We prepare custom studies, and provide public information our clients require to make informed strategic decisions, define objectives, and identify customer needs. With market information, our clients are better able to make informed, market-based decisions because they understand the trends and needs in high technology industries.

BioPlan Associates, Inc.
2275 Research Blvd., Suite 500
Rockville, MD 20850 USA
www.bioplanassociates.com
Tel: 301-921-5979

EDITOR

Eric S. Langer, MS, President, BioPlan Associates, Inc.

Eric S. Langer, MS, President, BioPlan Associates, Inc.

Mr. Langer is President and Managing Partner and President of BioPlan Associates, Inc., a biotechnology and life sciences consulting company that has been providing management and market strategy services, and technology analysis to biopharmaceutical and healthcare organizations since 1989. He has over 25 years' experience in biotechnology and life sciences management and market assessment. He is an experienced medical and biotechnology industry practitioner, strategist, researcher, and science writer. He has held senior management and marketing positions at biopharmaceutical supply companies. He teaches Biotechnology Marketing, Marketing Management, Services Marketing, Advertising Strategy, and Bioscience Communication at Johns Hopkins University, American University, and lectures extensively on pricing and channel management topics. Mr. Langer has a degree in Chemistry and a Masters in International Business. He has written and consulted extensively for companies involved in: large scale biopharmaceutical manufacturing, global biotechnology in China, Asia, and the Middle East; he has expertise in cell culture markets, media, sera, tissue engineering, stem cells, diagnostic products, blood products, genetics, DNA/PCR purification, blood components, and many other areas.

Ronald A. Rader, Senior Research Director

Mr. Ronald A. Rader has written and edited dozens of books and studies on biotechnology topics. He created the first biosimilars pipeline database, and is qualified with a B.S. (Microbiology), M.L.S. (Library Science). He has nearly 30 years' experience as a biotechnology, pharmaceutical and chemical information specialist and publisher. From 1988, he was Editor/Publisher of the Antiviral Agents Bulletin, the only periodical specializing in antiviral/HIV drug and vaccine development. In 1994, he published the Federal Bio-Technology Transfer Directory, abstracting and indexing all federal laboratory, e.g., NIH, inventions and technology transfers in biotech/biomedical areas, further marketed as an online database until 2000. Mr. Rader published Biopharmaceutical Products in the U.S. Market first in April 2001. Mr. Rader has been Manager of Information Services, Porton International plc, Prior to that he served as a biomedical/chemical information specialist/manager/analyst with companies including Gillette Medical Evaluation Labs., Gillette Co.; MITRE Corp.; Biospherics; Computer Sciences Corp. (CSC); Technical Resources Inc.; and Bio-Conversion Labs.

13th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production • April 2016

*A Study of Biotherapeutic Developers and Contract
Manufacturing Organizations*

CONTENTS

Methodology xxiii

CHAPTER 0: Demographics 1

0-1 Respondents' Area of Involvement.....	1
0-2 Respondents Qualifications.....	3
0-3 Facility Locations	5
0-4 Areas of Biopharmaceutical Manufacturing Operations	7
0-5 Production Operations, Phase of Development	9
Employees at Facility	12
Batches Run at Facility per Year	13

CHAPTER 1: INTRODUCTION AND DISCUSSION..... 15

1-1 INTRODUCTION: THE BIOPHARMACEUTICAL INDUSTRY.....	15
1-2 Some Biopharmaceutical Market Trends.....	17
1-3 Market Potential.....	19
1-4 Biopharmaceutical R&D Pipelines.....	20
1-5 Biosimilars in the Pipeline.....	23
1-6 Biopharmaceutical Approvals Generic.....	26
1-7 Global Biopharmaceutical and Recombinant Protein/MAb Markets	29
Overall Health of the Biopharmaceutical Sector	30
U.S. Industry Leadership Continues	32
Biopharmaceuticals in the Rest-of-the-World.....	32
1-8 Biopharmaceutical Markets by Product Class	35
mAbs are the Leading Product Classes	35
1-9 Biopharmaceutical Blockbusters.....	37
1-10 Commercial Product Expression Systems	38

1-11	Animal Derived Products and Biopharmaceuticals	39
1-12	Cost-containment and Price Controls	40
1-13	Future Trends in the Biopharmaceutical Industry	40
1-14	Overview of Biopharmaceutical Market Trends	41

CHAPTER 2: Overview of Critical Issues in Bioprocessing 45

2-1	Protein A Resins Continue to Serve Monoclonal Antibodies Manufacture Well, While Incremental Improvements Continue	46
2-2	Biosimilars: Cost Effective Manufacturing Creating Pressures for Mainstream Biologics.....	51
2-3	Training: From Startup to Market Production – A GxP Training Philosophy for Success	54
2-4	Facility Planning, Design and Engineering - The Changing Environment – Flexibility is a Key Attribute	60
2-5	Alternatives to Protein A.....	66
2-6	The Use of Membrane Chromatography throughout a Product’s Life Cycle.....	75
2-7	Continuous Bioprocessing and Perfusion: Single-use Technology Aiding to Increase Adoption.....	80
2-8	Mergers and Acquisitions in the Pharmaceutical Industry, 2015	84
2-9	The Bioprocessing Equipment Supply Chain: Materials in Single-use Products are the Weakest Link.....	89
2-10	Trends in Aseptic Bioprocessing Capacity for the Fill and Finish of Recombinant Biologics: An Analysis of US and European In-house Capacity and Capacity Utilization	94

CHAPTER 3: Emerging Issues in Biopharmaceutical Manufacturing..... 89

3-1	Industry Trends in 2015.....	101
	Productivity and Innovation.....	102
3-2	Budget Issues in 2016.....	104
	Budget Change Comparisons	107
3-3	Operational Changes	110
3-4	New Bioprocessing Products Development Opportunities in 2016	111
	Innovations in Single-use/Disposable Equipment.....	113
	Discussion of Needed Single-use Innovations.....	113
	Other Areas for Innovation	115
	New Product Development Focus, From 2010 to 2016	115
	New Product Development Areas: Biotherapeutic Developers vs. CMOs	117
	New Product Development Areas: U.S. vs. Western Europe vs. ROW	119
3-5	Factors in Biomanufacturing Creating Improvements.....	121
	Factors Improving Biomanufacturing Performance, 2010 - 2015	121

Factors Improving Biomanufacturing Performance, Biotherapeutic Developers vs. CMOs (2015 Data)	123
Factors Improving Biomanufacturing Performance, U.S. vs. Western Europe vs. ROW (2015 Data).....	125
3-6 Cost-Cutting Actions & Development Timelines	127
Cost-Cutting Changes: Specific to Outsourcing.....	129
3-7 Assay Development	131
3-8 Continuous Bioprocessing Operations Issues	133
3-9 Discussion	137
3-10 Perfusion Operations and Continuous Bioprocessing Trends	137
Continuous Bioprocessing: Trends and Opportunities.....	138
3-11 Selecting Bioreactors in New Facilities.....	140
3-12 Discussion: Industry Trends and Issues	144
Industry Growth and Adaptation.....	144
Cost Cutting Trends	144
Trends in Assay Development	145
Trends in Speeding Development and Approval Timelines.....	145
Trends in Bioprocessing Industry Desires for Improved Products and Services	146

CHAPTER 4: Capacity Utilization

4-1 Capacity Utilization Trends	147
Capacity Utilization Definitions.....	147
Relevance of Capacity Utilization	148
Capacity Utilization in Biomanufacturing, 2016.....	149
Capacity Utilization Changes Since 2004	150
Average Growth Rate in Capacity Utilization, 2006-2016.....	152
4-2 Capacity Utilization: CMOs vs. Biotherapeutic Developers.....	153
4-3 Capacity Utilization: U.S. vs. Western European Manufacturers.....	156
4-4 Respondents' Current Total Production Capacity	158
Mammalian Cell Culture.....	158
Estimated Bioreactor Capacity Distribution, Biotherapeutic Developers and CMOs	161
Biopharmaceutical Developers/Manufacturers as CMOs	163
Microbial Fermentation Capacity	164
Yeast Production Capacity	165
Insect cells Production Capacity	166
4-5 Current State of Capacity Utilization	167
Future Capacity Issues	168
4-6 Range of Titters for MAb Production	169
Annual Mab Titer Change, 2008-2016.....	171
4-7 Discussion: Capacity and Industry Trends	172
Capacity Utilization	172

CHAPTER 5: Current and Future Capacity Constraints 165

5-1 Current Capacity Constraints..... 179
 Respondents Experiencing No Capacity Constraints 181
 Respondents' Perception of Capacity Constraints, 2004-2016..... 181
 Perception of Capacity Constraints: Biotherapeutic
 Developers vs. CMOs 184
 Capacity Constraints: U.S. vs. Western European Biotherapeutic
 Developers & CMOs 186

5-2 Expected Capacity Constraints..... 188
 Respondents' Expectations of Capacity Constraints by 2021..... 188
 Expected Capacity Constraints by 2021: Comparing 2004 to 2016 Data..... 190
 Expected Capacity Constraints by 2021: CMOs vs. Biotherapeutic Developers ... 193
 Expected Capacity Constraints by 2021: U.S. vs. Western Europe..... 194

5-3 Factors Impacting Future Production Capacity..... 195
 Factors Creating Future Capacity Constraints 195
 Factors Creating Future Capacity Constraints, 2008 vs. 2016 197
 Factors Creating Future Capacity Constraints: Biotherapeutic
 Developers vs. CMOs 199
 CMOs' Capacity Bottleneck Projections, in Retrospect 201
 Biotherapeutic Developers' Capacity Bottleneck Projections, in Retrospect 202
 Factors Creating Capacity Constraints: U.S. vs. Western European Respondents 203

5-4 Key Areas to Address to Avoid Future Capacity Constraints 205
 Analysis of Areas to Avoid Capacity Constraints: Changing
 Perspectives, 2006-2016 207
 Key areas to Address to Avoid Capacity Constraints; Biotherapeutic
 Developers vs. CMOs: 2016 vs. Recent Years 209
 Key Areas to Address to Avoid Capacity Constraints: U.S. vs. Western Europe 211

5-5 Discussion 213
 Overall Capacity Constraints 214

CHAPTER 6: Future Capacity Expansions 207

6-1 Planned Future Capacity Expansions 219
 Planned Future Capacity Expansions, 2009-2021 220
 Planned Future Capacity Expansions by 2021; CMOs vs. Biotherapeutic
 Developers 222
 Planned Five-Year Capacity Expansions; U.S. vs. Western European
 Manufacturers 224
 Planned Future Capacity Expansions of >100%..... 226

CHAPTER 7: Outsourcing Trends in Biopharmaceutical Manufacturing 217

Why Outsource? 229
 Critical Outsourcing Operations 229
 Relating Outsourcing to Workforce Reduction 230

Strategic Manufacturing Planning	230
Future Projections	231
7-1 Current Outsourcing by Production System	232
Summary of Findings:	233
Facilities Currently Outsourcing No Production (All Production “In-house”), 2006-2016	235
7-2 Future Outsourcing	237
Biotherapeutic Developers’ Outsourcing, 2021 Projections, by System	237
Biotherapeutic Developers Outsourcing Some Production in 2021	239
7-3 Outsourced Activities in Biopharmaceutical Manufacturing	241
Comparison of Biomanufacturers’ Outsourcing, (2010-2016)	243
Increased Outsourced Activities, 24-month Projections	245
Outsourcing Activities Projected at ‘Significantly Higher Levels’, Comparison of 2010-2016 Trends	247
Average Percentage of Activities Outsourced Today	249
Comparison of Outsourcing Activities, 2010-2016	251
Change in Spending on Outsourcing Activities	253
7-4 Critical Outsourcing Issues	254
Selecting a CMO: 2016	254
Selecting a CMO, 2006-2016	256
Changes in Critical Issues when Considering a CMO, 2008-2016	258
7-5 CMOs’ Problems with Their Clients	260
7-6 Country Selections for International Outsourcing (Off-shoring) of Biomanufacturing	262
U.S. vs. Western European Respondents’ Outsourcing Destinations	264
Western European Respondents’ Outsourcing Destinations	269
5-Year Projection for Biomanufacturing International Outsourcing/Off-shoring	272
7-7 Offshoring Trends	274
5-Year Projection for Percentages of Biomanufacturing International Outsourcing/Off-shoring	276
7-8 Discussion of Outsourcing and Offshoring:	279
Selecting a CMO	282
<hr/>	
CHAPTER 8: Disposables and Single-Use Systems in Biopharmaceutical Manufacturing	271
8-1 Use of Disposables and Single-Use Systems	285
Disposables Applications in Biopharmaceutical Manufacturing	286
Trends in Disposable Applications: 2006-2016	288
Annual Growth Rate for Disposables Market Penetration / Usage	290
10-year Growth in Disposables Applications, Percentage-point Gains	292
Disposable Use by Stage of Production/Application	294
Use of Disposables: CMOs vs. Biotherapeutic Developers	296

8-2	Leachables and Extractables	298
	Paying for L&E Testing, 2015 vs. 2016	298
8-3	Reasons for Increasing Use of Disposables & Single-Use Systems.....	300
	Reasons for Increased Use of Disposables, 2006 through 2015	302
	Reasons for Increased Use of Disposables: Biotherapeutic Developers vs. CMOs (2015 data).....	304
	Single Most Critical Reason for Increasing the Use of Disposables	305
8-4	Factors That May Restrict Use of Disposables	307
	Factors That May Restrict Use of Disposables: Trends 2006-2015.....	309
	Factors that May Restrict Use of Disposables: CMO's vs. Biotherapeutic D evelopers (2015 data)	311
	Most Critical Reasons for Restricting Use of Disposables	312
	Most Important Reasons for Not Increasing Use of Disposables, 2008-2016	314
	Most Important Reasons for Restricting Use of Disposables: Biotherapeutic Developer vs. CMO	316
	Top Reasons for Not Increasing the Use of Disposables: U.S. vs. Western Europe Respondents	318
8-5	Standards Setting for Disposable, Single-use Systems	320
	Standardizing Single-use Designs	320
	Standardization Factors, 2013-2015.....	322
	Suppliers' Expectations for Standards Setting Bodies	323
8-6	Budgets for Disposable Systems	325
8-7	Need for Single-use Sensors, and Bioreactor Attributes	326
	Single-Use Adoption Issues	326
	Single-use Adoption Factors, U.S. vs Western Europe.....	327
	Single-Use Sensor Technologies	328
8-8	Recycling and Disposal of Single-use Plastics	330
	Waste Disposal of Single-use Devices	330
8-9	Satisfaction with Single-use Device Vendors	332
	Single-Use Attribute Importance Analysis	334
	Single-use Suppliers' Delivery Problems, 2013-2016	336
8-10	Single Use Operations and Trends	338
	Percentage of Unit Operations that are Single-Use	338
	Distribution of Responses	340
8-11	Discussion of Single-use Bioprocessing.....	341
	Single-use Advantages	341
	Growth in the Use of Single-use Systems	342
	Downstream Single-use Systems Use.....	343
	CMOs' Use of Single-use Equipment.....	343
	Downstream Bottlenecks Persist	344
	Modular: The Next Trend after Single-Use.....	344
	Single-use Equipment Sourcing, Quality Issues, and L&E Testing.....	345

CHAPTER 9: Downstream Purification	335
9-1 Impact of Downstream Processing on Capacity	351
Impact of Downstream Processing on Capacity, Biopharmaceutical Developers vs. CMOs	354
Impact of Downstream Processing on Capacity, U.S. vs. Western European Biomanufacturers	356
9-2 Specific Purification Step Constraints	358
Changes in Impact on Capacity of Purification Steps, 2008-2016.....	360
Specific Purification Step Constraints, U.S. vs. Western European Biomanufacturers	361
9-3 Downstream Purification Issues	362
Protein A and Alternatives	362
Changes in Perception of Protein A and Alternatives.....	363
Protein A Downstream Purification Issues, U.S. vs. Western Europe.....	364
9-4 mAb Purification Capacity Estimates	365
Current Upstream Production Titer vs. Max Capacity.....	365
9-5 New Downstream Processing Technologies	368
New Downstream Processing Solutions; 2010 – 2016	370
New Downstream Processing Technologies; Biotherapeutic Developers vs. CMOs	372
New Downstream Processing Technologies; U.S. vs. Western Europe	374
9-6 Improvements to Downstream Operations	376
Comparison of New Downstream Technology Implementation; Biomanufacturers vs. CMOs	378
Comparison of New Downstream Technology Investigations; U.S. vs. W. Europe vs. ROW	380
9-7 Discussion	382
CHAPTER 10: Quality Issues, Batch Failures, and PAT in Biopharmaceutical Manufacturing	371
Introduction	385
10-1 Hurdles to Implementing Process Analytical Technology	386
Trends in PAT, 2008-2016.....	386
PAT Adoption Will Increase	388
10-2 Batch Failure Frequency in Biopharmaceutical Manufacturing	389
10-3 Primary Cause of Batch Failures, Percentages of Failures	392
2016 Results included:	392
2015 results included:	392
10-4 Quality Problems in BioManufacturing Attributed to Vendors	397
10-5 Automation Implementation	399
Comparison of Implementation Plans 2009 - 2013.....	399

10-6 Quality Initiative Implementation	400
Initiating quality initiatives requires substantial organizational resources and commitment.	400
Comparison of Quality Initiative Implementation, 2009 - 2016	402
10-7 Global Quality Supply Management.....	404
Quality Supply Management-US vs. W. Europe	405
10-8 Discussion	406
Hurdles Hindering Implementation of PAT	406
Batch Failures Due to Single-Use Adoption or Continued Stainless Steel Use?	407
Quality Problems Traced to Vendors	407
Process Information Needs and Value Drive Automation	408
Quality Initiatives Are Becoming Commonplace and the New Industry Norm	408
Challenges to Implementing PAT, QbD and other Quality Initiatives.....	409
Supply Management Issues with Single-Use Systems.....	409

CHAPTER 11: Hiring, Employment Growth, and Training in Biopharmaceutical Manufacturing 395

Introduction	411
11-1 Hiring Trends.....	412
Trends in New Hires, by Area; 2008 – 2016	413
11-2 Hiring in 2021: 5-year Trends.....	415
11-3 Hiring Challenges Today.....	416
Hiring Difficulties; 2010 - 2016	418
Hiring Difficulties: U.S. vs. Western Europe.....	420
U.S. vs. Western Europe Hiring Trends	420
11-4 Training in Biopharmaceutical Manufacturing.....	422
Changes in Training for New Manufacturing Employees, 2009-2016.....	423
11-5 Discussion	424
Options Developing for Bioprocessing Training	424
Continued Growth in Biopharmaceutical Manufacturing Jobs	425

CHAPTER 12: Fill and Finish 411

Introduction	427
12-1 Demographics	427
Areas of Involvement	427
Geographic Location, Facilities	428
12-2 Trends in Fill-Finish and Related Bioprocessing Capacity	429
Analysis of US and European In-house Capacity and Capacity Utilization	429
Challenges in Estimating Fill-Finish Capacity	430
12-3 Current Fill-Finish Trends	431
Recent Industry Trends	433
Future Fill and Finish Trends	434

Suppliers' Innovation Trends.....	434
Industry Capacity Data.....	435
New Technology Implementation in Fill-Finish.....	436
12-4 Discussion	437
Voice of Industry:	437

CHAPTER 13: Suppliers to Biopharmaceutical Manufacturing and Life Sciences..... 425

Introduction	443
13-1 Demographics	443
Areas of Involvement	443
Location of Vendor Sales	446
Respondents' Primary Job	448
13-2 Growth Rate of Sales by Suppliers	449
Average Industry Growth Rate, By Segment	451
Vendor Sales Growth Rates, by Industry Segment, 2007 to 2016.....	452
Supplier Annual Sales, Distribution.....	454
13-3 Discussion of Vendor and Industry Growth	455
13-4 Budget Issues and Problems Faced by Industry Suppliers	456
Budget Challenges in 2016.....	456
Vendor Average Budget Changes for 2009 -2016	458
Vendor Pricing Changes	460
Future Price Changes	461
Supplier Budget Issues	462
13-5 Cost Cutting Actions by Vendors.....	462
Cost Cutting Actions, By Segment	464
13-6 Problems Clients Have with Their Vendors	466
13-7 Vendor Expansion Plans	468
Biopharma Vendor Business Trends, 2010 vs 2016.....	470
13-8 New Technology Areas in Development by Vendors.....	472
13-9 Sales Staff Training.....	478
Days of Training Provided	478
Areas where Training May Help Sales Staff Perform, Trends 2010 - 2016.....	478
Clients' Demands on Vendors.....	480
13-10 Biopharma Vendors' Financial Outlook for 2016	482
13-11 Discussion of Biopharma Suppliers.....	484
Bioprocessing Vendors Will See Continued Market Growth	484
Single-use Systems Are Increasingly Driving Sales	484
Trends Favor Increased Vendor Sales.....	485
Vendors are Offering More Services, Going for Larger Sales.....	485
Biopharma Suppliers in Emerging Regions	486

FIGURES

Fig 0.1:	Area of Primary Involvement in Biopharmaceutical Manufacturing, 2010 to 2016	2
Fig 0.2:	Respondents' Job Responsibilities, 2011 - 2016.....	4
Fig 0.3:	Facility Location	5
Fig 0.4:	Facility Location, by Region	6
Fig 0.5:	Biopharmaceutical Manufacturing Systems, (2007-2016) Trends	8
Fig 0.6:	Phase of Development of Surveyed Respondents (2006-2016) Trends	10
Fig 0.7:	Phase of Development of Surveyed Respondents, (U.S. vs Western Europe)	11
Fig 0.8:	Distribution of Employees at Facility, and Organization.....	12
Fig 0.9:	Distribution of Total Batches Run at Facility Last Year, by Scale of Production	14
Fig 1.1:	Investigational Drugs: Large Molecule (Protein Therapeutics), Worldwide, 2010 - 2015	21
Fig 1.2:	Worldwide Pipeline & Launched Products, Large Molecules, January 2015	22
Fig 1.3:	Current Worldwide Pipeline & Launched Products, Large Molecules, January 2015.....	23
Fig 1.4:	Number of Biosimilars in the U.S. Pipeline by Launchable Dates	24
Fig 1.5:	Biosimilars Launchable Dates by Sum of Current Reference Products Sales (\$millions)	25
Fig 1.6:	FDA Approvals of New Biopharmaceutical Products 1982-2015	26
Fig 2.1:	A GxP Training Philosophy for Success	56
Fig 2.2:	Trends in FDA Key Compliance Themes	59
Fig 2.3:	Antibody binding capacities on two prototype mixed mode membranes from Natrix Separations.....	77
Fig 2.4:	Example of chromatographic like separation achieved on a mixed mode membrane from Natrix Separations. (updated for this year's edition)	77
Fig 3.1:	SINGLE most important biomanufacturing trend or operational area, 2014-2016	103
Fig 3.2:	Biomanufacturers' Budget Shifts in 2016.....	105
Fig 3.3:	Approximate Average Change in Biomanufacturers' Budgets for 2016.....	106
Fig 3.4:	Average Biomanufacturers' Budget Change, 2009-2016	109
Fig 3.5:	New Product Development Focus Areas	112
Fig 3.6:	New Product Development Areas of Interest: 2010 - 2016.....	116
Fig 3.7:	New Product Development Areas of Interest: Biotherapeutic Developers vs CMOs	118
Fig 3.8:	New Product Development Areas of Interest: U.S. vs. Western Europe vs. ROW ...	120
Fig 3.9:	Factors in Biomanufacturing Performance Creating "Significant" or "Some" Improvements: 2010 – 2015 (Data from 2015).....	122
Fig 3.10:	Factors in Biomanufacturing Performance Creating "Significant" or "Some" Improvements: Biomanufacturers vs CMOs (2015 Data)	124
Fig 3.11:	Factors in Biomanufacturing Performance Creating "Significant" or "Some" Improvements: U.S. vs. Western Europe vs. Rest of World (2015 Data)	126

Fig 3.12:	Cost-Cutting Changes: Actions Undertaken During “Past 12 Months” Comparing 2011-2016	128
Fig 3.13:	Cost-Cutting Changes, Outsourced Jobs, by Segment, and Geography (2011-2016).....	130
Fig 3.14:	Biomanufacturing Assay ‘Areas’ Urgently Requiring New, Improved Testing Methods, 2011-2015 (2015 Data).....	132
Fig 3.15:	Perfusion Operations Issues: Perfusion vs. Batch-Fed Processes	135
Fig 3.16:	Perfusion Operations Issues: Comparison 2010 - 2016	136
Fig 3.17:	Continuous Bioprocessing Technologies Evaluation, Next 12 Months	138
Fig 3.18:	Likelihood of Implementing bioreactor, by type	142
Fig 3.19:	Likelihood of Implementing Single-use Bioreactors, Clinical Scale, 2012-2016	143
Fig 4.1:	Capacity Utilization, By System.....	150
Fig 4.2:	Capacity Utilization, By System, 2004-2016	151
Fig 4.3:	Change in Capacity Utilization, CAGR, 2006-2016.....	152
Fig 4.4:	Capacity Utilization, By System, Biotherapeutic Developer vs. CMOs.....	155
Fig 4.5:	Capacity Utilization, By System, U.S. vs Western Europe	157
Fig 4.6:	Current Production Capacity Distribution, Mammalian Cell Culture	159
Fig 4.7:	Production Capacity Distribution, Mammalian Cell Culture, 2011-2016.....	160
Fig 4.8:	Current Production Capacity Distribution, Microbial Fermentation.....	164
Fig 4.9:	Current Production Capacity Distribution, Yeast.....	165
Fig 4.10:	Current Production Capacity Distribution, Insect cells	166
Fig 4.11:	Mammalian Cell Culture Capacity Estimates 2003-2015.....	167
Fig 4.12:	Microbial Fermentation Capacity Estimates 2003-2015.....	168
Fig 4.13:	Range of Titres for Mabs Obtained at Various Production Scales, Distribution.....	170
Fig 4.14:	Average Mab Titre Trend 2008-2016.....	171
Fig 5.1:	Capacity Constraints, by Stage of Production	180
Fig 5.2:	Capacity Constraints, 2004 through 2016.....	182
Fig 5.3:	Capacity Constraints Trends, 2004-2016.....	183
Fig 5.4:	Capacity Constraints, Biotherapeutic Developers vs. CMOs	185
Fig 5.5:	Capacity Constraints, US vs. Western Europe.....	187
Fig 5.6:	Expectations of Capacity Constraints; by Stage of Production; Five-year Projections	189
Fig 5.7:	Expectations of Capacity Constraints: Five-year Projections Made in 2004-2016 ..	191
Fig 5.8:	Expectations of Capacity Constraints: Five-year Projections Made in 2004 thru 2021 (Trend Line)	192
Fig 5.9:	Five-year Projections for Capacity Constraints: Biotherapeutic Developers vs. CMOs	193
Fig 5.10:	Five-year Projections for Capacity Constraints: U.S. vs. Western Europe	194
Fig 5.11:	Factors Creating Future Capacity Constraints	196
Fig 5.12:	Factors Creating Future Capacity Constraints, 2008-2016.....	198
Fig 5.13:	Factors Creating Future Capacity Constraints: Biotherapeutic Developers vs. CMOs	200

Fig 5.14:	Factors Creating Future Capacity Constraints, U.S. vs. Western European Biomanufacturers.....	204
Fig 5.15:	Key areas to Address to Avoid Capacity Constraints	206
Fig 5.16:	Key areas to Address to Avoid Capacity Constraints; 2006-2016	208
Fig 5.17:	Key Areas to Address to Avoid Capacity Constraints; Biotherapeutic Developers vs. CMOs	210
Fig 5.18:	Key areas to Address to Avoid Capacity Constraints; U.S. vs. Western Europe	212
Fig 6.1:	Industry Average Planned Production Increase by 2021	220
Fig 6.2:	Planned Future Capacity Expansion: 5-year Estimates, 2009 through 2021	221
Fig 6.3:	Planned Future Capacity Expansion: 5-year Estimates; Biotherapeutic Developers vs. CMOs	223
Fig 6.4:	Planned Future Capacity Expansion: 5-year Estimates; U.S. vs. Western Europe.....	225
Fig 6.5:	Percent of Respondents Projecting Production Increases of over 100% by 2021; 5-year Trend	227
Fig 7.1:	Current Percent Production Outsourced; by System	234
Fig 7.2:	Biopharmaceutical Manufacturing Facilities Outsourcing NO Production, 2006-2016	236
Fig 7.3:	Future Outsourcing: Percent Production Outsourced; by System, in 2021	238
Fig 7.4:	Five-year Projections: % Biotherapeutic Developers Planning to Outsource at Least Some Production; Projections made 2007-2016	240
Fig 7.5:	Percent of Biomanufacturers Outsourcing at Least Some Activity Today	242
Fig 7.6:	Percent of Biomanufacturers Outsourcing at Least Some Activity Today--2010 - 2016	244
Fig 7.7:	Outsourcing Activities Projected to be Done at 'Significantly Higher Levels' in 2 Years.....	246
Fig 7.8:	Outsourcing Activities Projected to be Done at 'Significantly Higher Levels' in 2 Years, 2010 - 2016 Trends.....	248
Fig 7.9:	Current Outsourcing: Average Percentage of Activity Outsourced Today.....	250
Fig 7.10:	Estimated Average Percent of Activity Outsourced by Facilities, 2010 thru 2016 ...	252
Fig 7.11:	Change in Spending on Outsourcing for R&D or Manufacturing, 2012 - 2016	253
Fig 7.12:	Outsourcing Issues: BioManufacturing by Contract Manufacturing Organizations.	255
Fig 7.13:	Important Outsourcing Issues: BioManufacturing by Contract Manufacturing Organizations, Trends 2006-2016	257
Fig 7.14:	Important Outsourcing Issues: Response Shifts Over Time 2006-2016, Percentage Point Differences.....	259
Fig 7.15:	Most Common Mistakes Biopharmaceutical Sponsors Make with their CMOs, 2010-2013	261
Fig 7.16:	Country Selections as Destination for International Outsourcing of..... BioManufacturing (All Respondents)	263
Fig 7.17:	Percent U.S. Respondents Considering Country as 'Possible' Outsourcing Destination	265

Fig 7.18:	Percent U.S. Respondents Considering Country as “Strong Likelihood” or “Likelihood” as Outsourced Capacity Destination	267
Fig 7.19:	Percent Western European Respondents Considering Country as ‘Possible’ Outsourcing Destination.....	270
Fig 7.20:	Percent European Respondents Considering Country as “Strong Likelihood” or “Likelihood” as Outsourced Capacity Destination	271
Fig 7.21:	Percent of Biomanufacturing Operations Off-shored (International Outsourcing) within 5 Years	273
Fig 7.22:	Percent Biomanufacturers Performing at Least “Some” International Outsourcing/Off-shoring during Next 5 Years (2011-2016).....	275
Fig 7.23:	Estimated % Operations Done as International Outsourcing/Off-shoring during Next 5 Years (2011-2016)	277
Fig 8.1:	Usage of Disposables in Biopharmaceutical manufacturing, any Stage of R&D or Manufacture.....	287
Fig 8.2:	Usage of Disposables in Biopharmaceutical manufacturing, any Stage of R&D or Manufacture; 2006-2016.....	289
Fig 8.3:	Average Annual Growth Rate, Disposables, 2006-2016.....	291
Fig 8.4:	10-Year Percentage-Point Change in First-Usage of Disposables, 2006-2016	293
Fig 8.5:	Usage of Disposables in Biomanufacturing, by Stage of Manufacture (R&D - Commercial)	295
Fig 8.6:	Usage of Disposables in Biopharmaceutical Manufacturing; Biotherapeutic Developer vs. CMO.....	297
Fig 8.7:	Value of Useable Leachables and Extractables Data.....	299
Fig 8.8:	Reasons for Increasing Use of Disposable System Components in 2015 (data from 2015).....	301
Fig 8.9:	Reasons for Increasing Use of Disposable System Components, 2006-2015	303
Fig 8.10:	Single Most Critical Reason for Increasing Use of Disposables, 2009 - 2016.....	306
Fig 8.11:	Reasons for Restricting Use of Disposables (2015 Data).....	308
Fig 8.12:	Factors Restricting Use of Disposables, 2006-2015 (2015 Data).....	310
Fig 8.13:	Top Reasons for Not Increasing Use of Disposables, 2016.....	313
Fig 8.14:	Top Reasons for Not Increasing Use of Disposables, 2008-2016	315
Fig 8.15:	Top Reasons for Not Increasing Use of Disposables, Biotherapeutic Developer vs. CMO	317
Fig 8.16:	Top Reasons for Not Increasing Use of Disposables, U.S. vs. Western Europe	319
Fig 8.17:	Single-use/Disposables Standardization Factors (2015 Data)	321
Fig 8.18:	Single-use/Disposables Standardization Factors, 2013-2015 (2015 data).....	322
Fig 8.19:	Suppliers’ Perception of Organizations Responsible for Establishing Standards for Single-use Devices.....	324
Fig 8.20:	Single-use / Disposable Device Adoption Factors.....	326
Fig 8.21:	Single-use / Disposable Device Adoption Factors; U.S. vs Western Europe	327
Fig 8.22:	Need for Improved Single-Use Sensors, 2012-2016	329
Fig 8.23:	Single-use Recycling; Respondents’ Desires for Disposal vs. Actual Disposal Process.....	330

Fig 8.24:	Single-use Product Vendor Satisfaction Factors, 2008 - 2016.....	333
Fig 8.25:	Importance of Single-use Product Attributes vs. Level of Vendor Satisfaction	335
Fig 8.26:	Percentage Point Gap between Importance of SUS Product Attributes and Level of Satisfaction, 2013-2016	337
Fig 8.27:	Estimated Percentage of Facilities' Unit Operations that are "Single-use" (2014-2016).....	339
Fig 8.28:	Distribution of Responses, % Single-use Devices in Biomanufacturing	340
Fig 9.1:	Impact of Downstream Processing on Overall Capacity, 2008-2016.....	353
Fig 9.2:	Impact of Downstream Processing on Overall Capacity; Biotherapeutic Developers vs. CMOs	355
Fig 9.3:	Impact of Downstream Processing on Overall Capacity; U.S. vs. Western Europe	357
Fig 9.4:	Impact on Capacity of Depth, Chromatography and UF Purification Steps	359
Fig 9.5:	Impact on Capacity of Purification Steps: Experiencing at "Significant" or "Severe" Constraints, 2008 - 2016	360
Fig 9.6:	Impact on Capacity of Purification Steps, U.S. vs. Western Europe	361
Fig 9.7:	Issues Regarding Protein A Usage	362
Fig 9.8:	Issues Regarding Protein A Usage, 2009 - 2016.....	363
Fig 9.9:	Issues Regarding Protein A Usage; U.S. Vs. Western Europe.....	364
Fig 9.10:	mAb Operations: Current Upstream Production Titer (Distribution of Responses).....	366
Fig 9.11:	Bioreactor Yield at which DOWNSTREAM Purification Train Becomes Bottlenecked	367
Fig 9.12:	New Downstream Processing Solutions.....	369
Fig 9.13:	New Downstream Processing Solutions Comparison 2010-2016.....	371
Fig 9.14:	New Downstream Processing Solutions; Biotherapeutic Dev. vs. CMO	373
Fig 9.15:	New Downstream Processing Solutions; U.S. vs. Western Europe.....	375
Fig 9.16:	Improving Downstream Operations, 2011 - 2016	377
Fig 9.17:	Improving Downstream Operations; Biomanufacturers vs. CMOs	379
Fig 9.18:	Improving Downstream Operations (U.S. vs. Western Europe vs. ROW).....	381
Fig 10.1:	Hurdles Hindering Implementation of PAT (2008 - 2016)	387
Fig 10.2:	Batch Failure Frequency Distribution, 2009 - 2016.....	391
Fig 10.3:	Average Rates of Failure, by Primary Cause, and Phase of Manufacture	393
Fig 10.4:	Average Rates of Failure, by Primary Cause, and Phase of Manufacturing 2009 - 2016 (Commercial Manufacture)	394
Fig 10.5:	Average Rates Failure, by Primary Cause, and Phase of Manufacturing 2009 - 2016 ("Clinical" Scale)	396
Fig 10.6:	Quality Problems Traced to Vendors; 2008 - 2016	398
Fig 10.7:	Quality Initiative Implemented Currently, or within Next 12 Months	401
Fig 10.8:	Quality Initiative to be Implemented in "Next 12 Months," Comparing 2009 - 2016	403
Fig 11.1:	New Hires in Biopharmaceutical Manufacturing (2016)	412

Fig 11.2: Estimated Hiring, by Area, 2008-2016414

Fig 11.3: New Hires in Biopharmaceutical Manufacturing (2021)415

Fig 11.4: Areas Where Hiring Difficulties Exist in Biopharmaceutical Operations417

Fig 11.5: Areas Where Hiring Difficulties Exist in Biopharmaceutical Operations;
2010 - 2016419

Fig 11.6: Areas Where Hiring Difficulties Exist in Biopharmaceutical Operations,
U.S. vs. Western Europe421

Fig 11.7: Training for New Operations/Manufacturing Employees.....422

Fig 11.8: Average Annual Changes in Training for New Operations/Manufacturing
Employees, 2009 – 2016423

Fig 12.1: Fill-Finish Operation Type427

Fig 12.2: Fill-Finish Operation Location.....428

Fig 12.3: Fill-Finish Capacity Utilization Averages, 2015-2016430

Fig 12.4: Most Important Trends in Fill-Finish, 2015-2016432

Fig 12.5: Novel Fill-Finish Technology Implementation Plans within 24 Months,
2015 vs 2016436

Fig 13.1: Area of Biopharmaceutical Involvement, Vendor444

Fig 13.2: Area of Biopharmaceutical Involvement, Vendor Comparison 2010 to 2016445

Fig 13.3: Geographic Locations in which Vendors Currently Actively Sell Products
or Services, 2008 - 2016447

Fig 13.4: Respondents' Primary Job Function448

Fig 13.5: Average Annual Vendor Sales Growth Rate, 2007 - 2016449

Fig 13.6: Biopharmaceutical Supply Market Segment Sales Growth Distribution450

Fig 13.7: Average Annual Vendor Segment Sales Growth Rates, 2016451

Fig 13.8: Average Annual Vendor Sales Growth Rate, 2007 - 2016, by Segment453

Fig 13.9: Vendors' Approx. Annual Sales to Biopharmaceutical Segment %, 2012-2016.....454

Fig 13.10: Vendors' Average Budget Change for 2016457

Fig 13.11: Vendors' Average Budget Change for 2009 - 2016, Summary.....459

Fig 13.12: Vendors' Average Pricing Changes (2015 responses)460

Fig 13.13: Vendors' Average Pricing Changes, 2009-2015 Actual and 2016 projected462

Fig 13.14: Actions undertaken to reduce overall costs, prior 12 months, 2011 – 2016.....463

Fig 13.15: Actions undertaken to reduce overall costs in past 12 months, By Segment.....465

Fig 13.16 (See Fig 10.6; recap): Quality Problems Traced to Vendors467

Fig 13.17: Biopharma Business and Marketing Plans, 2016469

Fig 13.18: Biopharma Business and Marketing Plans, 2010-2016471

Fig 13.19A: Top New Technologies or New Product Development Areas473

Fig 13.19B: Top New Technologies or New Product Development Areas474

Fig 13.20: Areas Where Training May Help Sales Staff Perform Better; 2010 – 2016.....479

Fig 13.21: Client Demands of Vendors, Service and Support, 2012 - 2016481

Fig 13.22: Vendors' Optimism; Financial Performance 2011-2014, and
Projected Performance in 2016483

TABLES

Table 1.1	Biopharmaceutical Approvals Generic, 2015	27
Table 1.2	Number of Products in U.S. and European Markets*	29
Table 1.3	Summary of Worldwide Biopharmaceutical Revenue Growth by Product Class, 2007 and 2015	35
Table 1.4	Blockbuster Biopharmaceutical Products*	37
Table 1.5	Expression Systems/Host Cells for U.S./EU-Marketed Cultured Biopharmaceuticals	39
Table 2.1	Factors involved in facility decision-making.....	63
Table 3.1	Areas of Significant Projected Budget Percentage Increases for Biomanufacturing, Past Years:.....	108
Table 4.1	Western European Biomanufacturers' Average Capacity Utilization	156
Table 4.2	U.S. Biomanufacturers' Average Capacity Utilization	156
Table 4.3	Distribution of Mammalian Cell Culture Capacity, Product Manufacturers	162
Table 4.4	Compound Annual Change in Mab Titre, 2008-2016	172
Table 5.1	"Severe" or "Significant" Capacity Constraints, by Stage of Production, 2009-2016	180
Table 5.2	"Severe" or "Significant" Capacity Constraints today, W. Europe vs. U.S., 2010-2016	186
Table 7.1	Mammalian and Microbial Cell Systems, No outsourced production (i.e., all in-house manufacturing)	233
Table 7.2	Mammalian and Microbial Cell Systems, outsourced up to half of production.....	233
Table 7.3	Mammalian and Microbial Cell Systems, outsourced more than half of production	233
Table 7.4	Percent of U.S.-based Respondents Indicating Country as a "Strong Likelihood" or "Likelihood" as Outsourcing Destination, 2009-2016	268
Table 7.5	Percent of European-based Respondents Indicating Country as a "Strong Likelihood" or "Likelihood" as Outsourcing Destination, 2011-2016	272
Table 9.1	Percent experiencing "Serious" or "Some" capacity problems due to downstream processing 2008-2016	354
Table 9.2	Percent U.S. vs. Western Europe facilities experiencing "Serious" capacity problems due to downstream processing, 2009-2016.....	356
Table 9.3	Percent U.S. vs. Western Europe facilities not expecting to see bottlenecks due to downstream processing, 2008-2016	356
Table 9.4	Current Upstream Production Titer vs. Max Capacity.....	365
Table 10.1	Batch Failures, Average Weeks per Failure, per Facility, 2008-2016.....	389
Table 13.1	Selected "Other" Responses, New Technology Areas in Development	475
Table 13.2	Average Vendor Sales and Technical Training Days, 2011 - 2013	478

METHODOLOGY

This report is the thirteenth in our annual evaluations of the state of the biopharmaceutical manufacturing industry. The strength of this study's methodology remains in its breadth of coverage, which yields a composite view from the respondents closest to the industry. This year, BioPlan Associates, Inc. surveyed 222 qualified and responsible individuals at biopharmaceutical manufacturers and contract manufacturing organizations in 27 countries; plus 191 industry vendors and direct suppliers of materials, services and equipment to this industry segment. Using a web-based survey tool, we obtained and evaluated information regarding respondents' current capacity, production, novel technology adoption, human resources, quality, and outsourcing issues. We assessed respondents' projected reasons for bottlenecks, and their perception of how these bottlenecks might be resolved.

We continue to provide additional in-depth analysis of specific issues affecting the industry in Chapter 2. These Monographs cover the events shaping the past year, and evaluate how they will affect, or create trends that will shape biopharmaceutical manufacturing over the next five years. We also have included this year a chapter on Fill-and Finish operations. Over the past few years, advances in technologies, drug delivery, and single-use applications have increasingly made this segment an area of interest for innovation.

To ensure comprehensive global coverage, we partnered with world-wide organizations to ensure the most accurate overview of the worldwide biopharmaceutical industry. Our industry partners are included in our acknowledgment section. In addition, to support this coverage, we also include acknowledgment of our media partners, whose assistance enabled us to reach the high quality of respondents required in this quantitative analysis.

Further information on methodology, breakouts on specific segments, and data from earlier surveys may be obtained by contacting us at the address below.

Eric S. Langer
President
BioPlan Associates, Inc.
2275 Research Blvd., Suite 500
Rockville, MD 20850
301-921-5979
elanger@bioplanassociates.com
www.bioplanassociates.com

CHAPTER 0: DEMOGRAPHICS

Survey respondents included a diverse group of biopharmaceutical senior managers and executives covering a spectrum of global biopharmaceutical and CMO firms. In addition, in Chapter 13, we include responses from global suppliers and vendors in this industry. As in previous years, we included firms of all sizes. While we specifically sought input from larger manufacturers with substantial current capacity, we also obtained data from mid-tier and smaller companies with clinical scale production, and also from companies using CMOs for product manufacture and from CMOs. Respondents had a broad range of responsibilities, though all were directly involved with manufacturing in some way. Most were senior staff within their organizations.

This was an international effort, and we received responses from individuals at organizations around the world, including input from facilities in 27 countries.

The diversity of respondents provides a comprehensive view of the industry from those closest to the present state of their organizations; those with a good understanding of the current and future business drivers, and their company's manufacturing plans and needs. This offers a means for understanding the industry and its future course. The breakdown of organizations into CMOs and biotherapeutic manufacturers provides insights into two major segments of the industry. These two types of organizations have different business drivers, risk profiles, and costs of capital.


0-1 RESPONDENTS' AREA OF INVOLVEMENT

Of the 222 biopharmaceutical manufacturers and contract manufacturing organizations (CMOs) staff responding to this year's survey, 23.0% were primarily involved in *Large-scale cell culture production for therapeutics*, slight decrease down from 23.6% last year, and continued decline from 27.7% in 2014. 27.0% were involved primarily in *Process Development for biopharmaceutical manufacturing*, an almost 6% percentage point increase from 21.9% last year, and back up to levels seen in 2013; 12.6% were involved in scale-up (or clinical-scale) production for biopharmaceuticals only, a small increase from 11.0% last year.

Respondents involved with *Large-scale Microbial Fermentation* for therapeutics accounted for 5.9%, an increase in 1.7% percentage points and a change from last year's decline of 4.2%, and 8.1% of respondents indicated they were primarily involved in Vaccine production, down from 9.3% reported last year. 'Other' large-scale biopharmaceutical manufacturing respondents accounted for 6.3% of the total this year, a decline from 9.7% in 2015, and 'Other' contract manufacturing (CMO) for biopharmaceuticals accounted for 2.3% of respondents, down from 3.8% last year. Lastly, 9.5% were employed in *Large-scale contract manufacturing (CMO) for biopharmaceuticals*, the slightest decrease from most prior years. This year, 5.4% of

respondents accounted for Fill/Finish operations, a slight decline from 6.8% last year. Overall, the makeup of respondents remains overall consistent with prior years' studies, with the most significant changes seen in Process Development for biopharmaceutical manufacturing and 'Other' large-scale biopharmaceutical manufacturing. Despite variations, including decreases, in reporting involvement in aspects of biopharmaceutical manufacturing, this year's data continues to fall within the range defined by prior years' data reporting, with the relative rankings remaining largely unaffected.

Fig 0.1: Area of Primary Involvement in Biopharmaceutical Manufacturing, 2010 to 2016




0-2 RESPONDENTS QUALIFICATIONS

Respondents were asked about their areas of responsibility, as indicated by job titles. Over 92% had titles of *VP, Director or President/CEO*, consistent with last year's 91.7% and nearly 88% in 2014. *VPs, Directors or Managers of Manufacturing, Production, and Operations* comprised 27.1% of respondents, a sharp decline from 34.2% last year. Combining *VPs* with *Process Development Directors and Managers*, the percentage comes to 63.6%, a 3.3%-point decrease from last year's 66.9%, and closer to 62.7% reported in 2014.

Biopharmaceutical *Scientist or Engineer* respondents lacking *VP/Director/Manager* responsibilities in *Process Development, R&D or Production* made up 7.9%, another persistent decline from prior year respondents (8.3% in 2015 and 12.1% in 2014.) This year, 15.8% of respondents indicated they were *VPs, Directors or Managers of QA, QC, Validation, or RA*, the largest number of respondents in this area since data collection started in 2011. *Presidents/CEOs* represented 7.4% of respondents, a reversal from the decline seen in prior years; and *VPs or Directors of R&D* accounted for 5.4% of respondents, still averaging similar totals seen in past years. The largest percentage change this year continues for those reporting *VP or Director: Operations* responsibilities, with a 6.8%-point decrease from last year.

Fig 0.2: Respondents' Job Responsibilities, 2011 - 2016

Which best describes your primary job responsibilities?




0-3 FACILITY LOCATIONS

This year we surveyed respondents based in 27 countries. Almost 62% of the respondents were from the United States, with the Northeastern U.S. continuing to make up the largest group of respondents in the U.S., at 33.3%, no change from last year's total. Respondents from Western Europe made up 21.4% of the total, a continued increase from last year's 19.7%. Other countries in the survey ("Rest of World") made up 17.5% of the respondents.

Further information about biopharmaceutical manufacturing facilities worldwide is available at the *Top 1000 Global Biopharmaceutical Facilities Index Web* site from BioPlan Associates (www.Top1000Bio.com).

Fig 0.3: Facility Location




We note that U.S. respondents continued its steady rate at 61.2%, down 1.7%-points from 62.9% last year, 65.8% in 2014, and nearly consistent with the 61.7% U.S. respondents in 2011. Western European responses remain relatively constant near 20% since 2011, with the slightest increase to 21.4% this year.

This year ROW responses only rose 0.1 point from last year's 17.4%, although still off the peak of 22.0% in 2013. This year we see a slight uptick in Western European respondents and U.S. bioprocessing professionals remain to be more motivated to participate in this and other industry surveys.

Fig 0.4: Facility Location, by Region

**Respondents' Facility Location by Region
(Biotherapeutic Developers and CMOs)**



Western Europe respondents include: Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands, Portugal, Spain, Sweden, Switzerland, and the United Kingdom.

“Rest of World” respondents include: Australia, Canada, Chile, India, China, Iran, Singapore, Egypt, Japan, Russia, Estonia, Israel, Argentina, Brazil, Bulgaria, Cuba, Korea, Lithuania, New Zealand, Poland, Slovenia, South Africa, and Taiwan.

0-4 AREAS OF BIOPHARMACEUTICAL MANUFACTURING OPERATIONS

Mammalian Cell Culture systems continue to dominate product development and manufacture. Further, a large percentage of products in the pipeline entering the market are mammalian-expressed, including various recombinant monoclonal antibody products. With the recent and on-going increases in mammalian system titers and yields, many facilities are standardizing using mammalian vs. microbial systems; in some cases, even products that could be manufactured in microbial systems are now being considered for manufacture in mammalian systems, if these will get the job done, such as to produce pre-clinical or early clinical supplies.

This year, we see a decrease in Mammalian Cell Culture and Microbial Fermentation; small upticks in the overall percentage of respondents for Yeast and *Insect cells*.


Respondents involved in *Mammalian Cell Culture* decreased from last year's study (79.3% vs. 85.9%). Although respondents were permitted to select multiple platform systems, the modest drop in mammalian systems is possibly due to more facilities standardizing on one or another platform.

We saw a similar decrease for *Microbial Fermentation* systems where 37.5% of respondents noted involvement in this area, a 7.4%-point decrease from the previous year (44.9%), and continuing the decrease seen in prior years.

On the other hand, less common systems including yeast, plant saw modest increases. For this year, 17.4% said that their facility had production operations in Yeast, a reversal from the decline seen in recent years. The percentage of those involved with microbial manufacture, including Plant Cells, saw a slow rise over the past couple of years, which still continues in this year's study (9.2%). *Insect cells* declined to 2.7% this year, going back to levels seen in 2014.

Fig 0.5: Biopharmaceutical Manufacturing Systems, (2007-2016) Trends

***In which of the following does your facility currently have production operations for biopharmaceutical products?
2007- 2016 (Trends)***




0-5 PRODUCTION OPERATIONS, PHASE OF DEVELOPMENT

We identified the phases of pipeline development in which respondents' organizations (companies) had products. This year, over half (52.5%) of respondent companies had *R&D* biopharmaceutical operations, a reversal from last year's decline of 47.8%, and readjusted with levels seen in prior years. 57.6% indicated their company having *Preclinical* operations, a continued small decline from last year's 59.2% and 63.8% in 2014. Respondent organizations involved with R&D have shifted back to their relative 50% level seen in almost all prior years, but still remain much lower than the 73.3% in 2006. Preclinical started at 75.4% in 2006, remained declining each year after, and has remained consistently near the 60% mark, as seen in this year's 57.6%.

The percentage of respondents whose companies have biopharmaceutical products on the market has slightly increased to 54.2%, up from 53.2% last year. The percentage involved with products in Phase III development decreased to 55.9% this year, down from its marked increase last year (60.7%), and relative to prior years.

This area continues to see small fluctuations as the industry continues its overall maturation, with most respondents now employed by companies with revenue streams from marketed biologics. In fact, 2009 has been widely noted as the year the biopharmaceutical industry finally, as a whole, turned a profit. Overall, the employers of the biopharmaceutical manufacturing professionals interviewed are rather evenly distributed over the pipelines from pre-clinical through commercial manufacturing, with each phase being worked on by 50+% of survey respondent organizations.

Fig 0.6: Phase of Development of Surveyed Respondents (2006-2016) Trends




This year, we see Western Europe respondents indicating a higher response of involvement by their companies with *Preclinical* products at 71.1% vs. 57.7% for the U.S., a major shift from last year in which W.E. respondents indicated only 59.0% vs. 61.4%, respectively.

European respondents involved in commercial products declined significantly to 52.6%, (from 61.5% last year), while increasing for the U.S. to 56.7% (from 50.4% last year).

The U.S. continued to report lower percentages in Phase I clinical trials this year vs. Western Europe (57.7% vs. 65.8%), both global areas down from 67.7% and 69.2%, respectively, last year. Another major shift seen this year is significantly lower percentage in *Phase III* clinical trials for Western Europe vs. U.S., (57.9% and 60.6%), a big decrease from last year (71.8%) for Western Europe.

Fig 0.7: Phase of Development of Surveyed Respondents, (U.S. vs Western Europe)




Employees at Facility

To evaluate issues such as capacity, disposables usage and other factors, we asked respondents for the number of staff within their own facility, and within their total organization. The largest percentages of respondents remained to be at facilities with 100-499 employees. Continuing the trend, the largest share of respondents, 41.6%, tend to be from organizations with greater than 5,000 employees. This distribution reflects the distribution of bioprocessing and other professionals' employment in the (bio)pharmaceutical industry. This includes the increasing involvement and even dominance of larger companies in biopharmaceutical R&D and products marketing. And with most Big Pharma type companies continuing to move into biopharmaceuticals, the dominance of large companies as employers of biopharmaceutical manufacturing professionals will continue.

Fig 0.8: Distribution of Employees at Facility, and Organization

About how many employees currently work at your facility & organization? (n=178)



Batches Run at Facility per Year


To continue our evaluation of issues such as batch failure rates, and to ensure we are capturing organizations involved in significant manufacturing processes at various scales of manufacture, we asked again this year for the number of batches or production runs the respondent's facility (not the organization) ran over the past 12 months.

We found that for '*Clinical Scale*' manufacturing, the largest number of facilities reported producing between 1 and 20 batches per year (71.4%), a continual increase from 63.5% last year and 60.9% in 2014. At the '*Commercial Scale*', only 10% reported producing over 150 batches per year, down from 14.9% last year; most (among those manufacturing) reported running between 0-70 batches per year (74.2%), up from 71.5% last year.

To compare consistency of respondents' operations, year-by-year, we evaluated the number of batches run/year. This year (asking about 2015), we found between "0-10" batches were run by 55.4% (Clinical Scale) and 42.5% (Commercial Scale) of respondents. So, fewer than half of respondents are operating at with no, or a low number of production runs for Clinical manufacturing, while 35% are at facilities doing ≥ 100 commercial runs/year.

Looking at prior years' studies, we have found that companies are running more batches this year. While Commercial Scale "0-10" batches remained consistent with 2009 levels (42.5%), Clinical Scale "0-10" batches have sharply increased to 55.4%, up from 40.5% last year. This increase in clinical manufacturing runs suggests an increase in preclinical studies and candidate products entering development.

Fig 0.9: Distribution of Total Batches Run at Facility Last Year, by Scale of Production



CHAPTER 1: INTRODUCTION AND DISCUSSION

1-1 INTRODUCTION: THE BIOPHARMACEUTICAL INDUSTRY

The pharmaceutical and biopharmaceutical industries remain active, profitable and growing economic activities, despite not all that long ago having recovered from worldwide economic problems. There are estimated to be over well over 10,000 therapeutics in R&D, both drugs (chemical substance pharmaceuticals) and biopharmaceuticals (biotechnology-derived pharmaceuticals), with nearly 40,000 ongoing (or recently reported) clinical trials. Among these, an estimated 40% or likely over 4,000-5,000 candidate products in R&D are biopharmaceuticals. A significant portion, about 1,400 products in the development pipeline, is follow-on biopharmaceuticals, mostly biosimilars but also a large number of biobetters. This industry activity represents a considerable increase from as short as five or more years ago and also reflects a basic shift in the pharmaceutical industry from small molecule drugs to biopharmaceuticals for new, innovative and profitable products. The large number of biosimilars and biobetters in development indicate the maturation of the biopharmaceutical industry, as its current major products start to go off-patent.

However, as companies of all sizes, particularly Big Pharma-type companies that now do most biopharmaceutical R&D, continue to cut back on expenses as much as possible and consolidate R&D, some may be concentrating more on fewer products, so this may tend to shrink the pipeline somewhat. But in terms of biopharmaceuticals, any such decrease in overall large pharmaceutical company R&D is likely currently being counter-balanced by established, including Big Pharma companies, companies increasingly moving into biopharmaceuticals. But even if the pipeline is shrinking (which will only be evident in hindsight), this is not necessarily an indicator of problems. Any pipeline shrinkage may simply reflect the industry doing a good or better job in eliminating less promising candidates before they enter in early-stage clinical trials. Thus, a somewhat shrinking clinical pipeline could indicate better selection of products for development with a higher percentage ultimately being successful. This 'failing faster,' i.e., earlier in development, is much less costly and disruptive than products failing later in development. If industry is doing a better job of weeding out poor candidate products earlier, industry may actually be on track for increased future success and increased productivity and profits, with fewer costly late-stage failures and a higher percentage of pipeline products making it to the market.

The pharmaceutical R&D pipeline and industry are becoming increasingly dependent on biopharmaceuticals. These products are being developed by an ever-increasing cross-section of the pharmaceutical industry, including Big Pharma and even generic drug companies, with many of these active in developing biosimilars. These sources, along with

smaller biopharmaceutical developers, which have been the traditional original source for most innovative biopharmaceuticals, before licensing by larger companies, are continuing to expand the global biologics pipeline. Biosimilars are bringing in many new biopharmaceutical players. And new entrants based in China, India and other developing countries are also increasingly entering biopharmaceutical R&D. Thus, an increasing number and percentage of new pharmaceuticals entering the market will be biopharmaceuticals vs. small molecule drugs; and these will likely originate from more diverse sources. Combine this with biopharmaceuticals generally costing much more and providing higher profit margins, and the pharmaceutical industry will increasingly be dependent on biopharmaceuticals for profits, innovation and its basic survival.

As biopharmaceuticals become an even more important part of the pharmaceutical industry, many new players are entering the field and most current manufacturers are expanding their bioprocessing capacity. Not only must bioprocessing output (if not liter capacity) expand to handle manufacture of an increasing number of approved products and higher volumes as markets for many products further expand, e.g., with approvals for new indications and growth in international markets, the industry must also be capable of handling a large number of pipeline products. Most recent large capacity expansions generally have involved building large fixed stainless steel bioreactor-based bioprocessing systems for commercial product manufacture, while production of supplies for R&D and clinical testing are now essentially dominated by use of single-use/disposable bioreactor-based systems, with this requiring much less facilities and infrastructure investment and construction. However, recently there has been significant increase in new single-use commercial-scale manufacturing facilities under construction and coming online. This now includes modular facilities. The strategic importance of biopharmaceutical manufacturing and manufacturing capacity are increasing, and understanding the markets for biopharmaceuticals and bioprocessing technologies and services is becoming ever more important to those in the industry.

Planning and decision-making concerning the manufacture of biopharmaceuticals are becoming more complex as companies continue to implement cost-saving efforts, often including cutting back on the number of products in their development pipelines, and outsourcing even more support and even critical tasks. In addition, manufacturers must choose from an ever-increasing number and diversity of bioprocessing options. This includes new and improved cell lines and genetic engineering/expression systems technologies; bioprocessing equipment, including new and improved single-use and stainless steel equipment; and outsourcing manufacturing to CMOs which are expanding their capacity, technologies, and service offerings. Increasingly, companies must make difficult and costly strategic decisions about commercial manufacture earlier in product development.

A number of questions need to be answered by biopharmaceutical developer even before a product is shown effective in clinical trials. These include aspects such as:

- Should we use an older, off-patent expression system or a new, much higher yield, but more likely royalty-bearing system?
- Should we use single-use/disposable or fixed stainless steel bioprocessing equipment for clinical supplies manufacture?
- If we use single-use bioprocessing systems to support development, do we want to be among the pioneers to use single-use equipment for commercial manufacture or should we stick with familiar, trusted, but more expensive and labor-intensive, fixed stainless steel equipment for commercial manufacture?

Effective planning within the biopharmaceutical and bioprocessing markets is required to avoid problems later on. This demands a high level of leadership, partnership, information sharing and communication between manufacturers, CMOs and bioprocessing technology and equipment suppliers as they develop new manufacturing technologies, devices and capacity to keep pace with industry needs. Strategic production decisions must be based on solid bioprocessing and sales projection data, combined with a broad understanding of trends and effective benchmarking of capacity and production issues.

This study provides an on-going evaluation of the vital manufacturing trends shaping this industry, and is designed to help keep those in the industry aware of the external trends and issues affecting biopharmaceutical manufacture decision-making.

1-2 SOME BIOPHARMACEUTICAL MARKET TRENDS

The biopharmaceutical industry survived the relatively recent worldwide economic downturn. In fact, the industry has done rather well for itself during what for most other industries was a recovery period – not contracting or losing much at all in recent years – and has been showing consistent clear signs of full recovery and renewed growth. In fact, the biopharmaceutical industry continues to remain dynamic and growing. This year, as in 2015 and prior years, survey results show that companies are spending and investing more in their R&D, new technologies, bioprocessing capacity, staff and other infrastructure. Companies, particularly larger and more established ones, are continuing to aggressively look for opportunities to cut costs and increase efficiency, with this continuing to benefit contract manufacturing and research organizations (CMOs and CROs). Prior rather common severe arbitrary cuts in staff and divestment of facilities have largely ended, but this may simply reflect reaching the limits of eliminating in-house expertise and facilities. Some specific trends are discussed below.

The industry is healthy and its status is improving: The world market for biopharmaceuticals is now over \$200 billion; growing at a healthy rate. New products and new markets, particularly internationally, continue to support market growth. The world market for recombinant protein therapeutics is now \geq \$150 billion, with non-recombinant vaccines and blood/plasma products comprising the remainder. The continued high growth rate in biopharmaceutical markets (revenue) will continue to drive investment in the industry, including at the expense of traditional small molecule drug development. Biopharmaceuticals vs. drugs have simply proven themselves to be profitable investments, e.g., with much higher profits per sale and likelihood of attaining commercial success, including capturing market share, with this often simpler or more straightforward with innovative biopharmaceuticals. Also, biopharmaceuticals vs. drugs tend to be developed for diseases and indications generally lacking current good options for treatment, assuring them of eager markets upon launch. A large portion of biopharmaceuticals coming to market still involve treatment of ignored or currently untreatable indications, making them particularly welcome and needed. Many new entrant companies of all sizes and types, including generic drug and foreign companies, are developing biosimilars and plan to use these to establish them in the industry. This is resulting in a significant increase in the number of players in the biopharmaceutical industry.

Overall, 2016, like 2015, is fully expected to be a good year for the biotechnology and biopharmaceutical industries, with these remaining viable, relatively insulated from the worst of any major economic problems, growing and well-positioned for solid future growth.

Cost-containment and Controls: The past year was noisier than recent prior years in the U.S. in terms of protests over exceedingly high pharmaceutical prices. Most attention was directed not to biopharmaceutical products, rather to a few expensive hepatitis C drugs and marketed drug products where prices were drastically increased. The arrival of biosimilars in the U.S. and other major markets may take some pressure off of calls for increased government cost-containment and price controls in the U.S. and other major markets. In the U.S. and many other markets worldwide, drugs for chronic hepatitis C that are actually curative but set records for related costs are resulting in increased attention to pharmaceutical pricing practices. In some other countries, cost containment and government-directed cost controls continue to adversely affect biopharmaceuticals. This includes the U.K. National Institute for Health and Clinical Excellence (NICE) issuing more product reviews rejecting some biopharmaceuticals as too expensive and not cost-effective for use by the country's National Health Service (NHS), effectively making these products non-marketable in the U.K. In the U.S., insurance providers continue to increasingly effectively take control of prescriptions away from physicians and consumers, forcing use of products for which they have secured preferential prices and often simply just refusing to pay for expensive biopharmaceuticals that they (not the prescribing physician and his patient) do not consider the most appropriate. As biosimilars become available, much as with generic drugs, U.S. insurers will surely force physicians, pharmacists and consumers to use these rather than more expensive innovator products.

Manufacture in Developing Countries is Increasing: Biopharmaceutical manufacture outside of the usual major market countries is increasing, as indicated by BioPlan's *Top 1000 Global Biopharmaceutical Facilities Index* (www.top1000bio.com), which ranks facilities worldwide in terms of known or estimated capacity, employment, and production. Much new and increased capacity is being added internationally, with biopharmaceutical markets in many developing countries rapidly growing and domestic/regional companies increasingly serving these markets, often with biogeneric or other outright copies of innovator products that are simply marketed as substitutable for the innovator product (without much, if any, real testing, and without real GMP-quality manufacturing). Developed country-based companies seeking to expand in international markets will increasingly have to deal with such local/regional competition. Another factor that will result in increasing manufacture in lesser-developed countries is that these countries' governments are increasingly seeking to assure domestic manufacture of biopharmaceuticals being sold in their markets. Already, many countries are starting to tell vaccine manufacturers that they want products for their markets manufactured in-country, preferably or requiring this be done by locally-owned or joint venture companies. And as single-use equipment and manufacturing technologies continue to improve and, particularly, as modular bioprocessing facilities enter the market, foreign countries (or their proxy/subsidiary companies) will increasingly undertake manufacture of needed products, such as commonly-used vaccines, with or without the assistance and participation of original product developers and current manufacturers. This can be seen in countries such as Brazil, and Cuba has long domestically manufactured diverse biopharmaceuticals for itself and international commerce.

Worldwide Standardization of Manufacturing: Particularly with larger companies, as more biopharmaceutical manufacturing is performed worldwide, companies are working to standardize their products and manufacturing processes on a worldwide basis. For many, this includes having 2nd- or even 3rd-source geographically-spread facilities either actively manufacturing or serving as backups, having received approvals for manufacture for the U.S. and other major markets. Adoption of single-use and modular bioprocessing systems for commercial manufacturing will accelerate this trend.

1-3 MARKET POTENTIAL

The biopharmaceutical market will continue to expand. There are currently 1,000s of therapeutics in R&D, including >40% now being biopharmaceuticals. This shift towards biopharmaceuticals reflects a fundamental shift within the pharmaceutical industry, with the largest traditionally small molecule drug-oriented Big Pharma companies moving heavily and rapidly into biopharmaceuticals. These companies are increasingly developing their own, licensing in or otherwise acquiring more biopharmaceutical products. For these companies and others, biopharmaceuticals provide higher revenue (cost more) and profits per sale, and with biopharmaceuticals often requiring more complex detailing and other sales support, increasingly fit well with the resources and marketing-intensive business models of large international pharmaceutical companies. Overall, there is a major shift towards biopharmaceutical R&D, manufacturing and marketing, often at the expense of traditional small molecule drug candidates.

However, due to economic concerns, all pharmaceuticals, particularly biopharmaceuticals which tend to be the most expensive, face increasing cost containment and control efforts worldwide. The U.S. remains the world's main pharmaceutical market, including in terms of sales and profits. Government-based cost-containment and control efforts remain limited in the U.S. Despite political demands for lowering pharmaceutical expenses for government programs, such as Medicare for older patients, the major U.S. health care overhaul legislation ("Obamacare") enacted in late 2010 is having minimal, apparently no, negative impact on biopharmaceutical usage. If anything, this health care overhaul actually provides continued long-term support for use of innovative (bio)pharmaceuticals, particularly if the alternatives are no treatment (none being available) are involve use of less effective therapeutics. Cost-containment and control efforts can be expected to increase in most other countries, particularly, those already having implemented cost controls, with expensive biopharmaceuticals being an easy target for elimination or reduction. Along these lines, India has substantially boosted its price controls and generics-favoring policies, including not allowing pharmaceuticals to be marketed by trade name (only by generic name).

However, since most biopharmaceuticals are used for indications for which there are few, if any, alternatives; the overall market is rather protected from widespread cost-containment and controls. Those countries that have imposed cost controls, so far, generally each represent small markets. Improved manufacturing methods and cost management for biopharmaceutical production will continue to slowly advance, which will tend to reduce the cost of goods, which may result in lower consumer prices. With continued reductions in manufacturing costs, including better process monitoring, higher-yield expression systems, and increased use of more cost-effective single-use/ disposable bioprocessing systems, biopharmaceuticals appear to be positioned to further increase their role in world pharmaceutical markets.

The world biopharmaceutical market is currently likely now over \$200 billion/year. This continues to grow worldwide at $\leq 15\%$ /year, making biopharmaceuticals a fairly recession-proof, growing and profitable industry. The market for recombinant proteins now is about \$150 billion. Much of this growth in biopharmaceutical revenue is due to an increasing number and sales of recombinant monoclonal antibodies, now a >\$50 billion market. These products have been shown to be rather reliable in terms of development and reaching the market, with antibodies generally being very specific, targeted, not causing severe adverse effects and by now familiar and well-received in the marketplace. Recombinant monoclonal antibody sales will further rapidly increase in coming years as new products enter the market and approved indications are expanded for existing products, while new biosimilars may reduce overall prices slightly, but these lower price may well result in higher sales.

But despite the industry being healthy and growing, broader economic issues, the broader pharmaceutical industry's long-term problems with innovation and profits, investors now coming to expect constant cut-backs, layoffs, increased outsourcing, etc. will continue to force biopharmaceutical companies of all size to cut costs wherever possible. This is shown in this year's survey data showing that the industry continues to recognize the need for continual improvements in performance and optimization of R&D, manufacturing and marketing. Financing, particularly for new smaller companies, although reported to have increased in 2015, will tend to remain restricted in 2016. Many companies of all sizes are having to seek alternative funding methods, increase their collaborations and licensing (vs. conducting in-house R&D), decrease the number of candidates in development, and are otherwise taking steps to make themselves more efficient and productive.

The use of contract manufacturing organizations and the use of single-use bioprocessing equipment are making product manufacture, particularly for R&D and clinical trials, more efficient and often less costly. Especially for smaller and under-funded companies, going with CMOs for production or using single-use equipment for in-house candidate product manufacture are the only viable options. These approaches reduce up-front capital and financing needs, because companies can avoid \$50-\$150 million or more facilities costs for construction of fixed, dedicated stainless steel bioreactor-based bioprocessing systems, while a typical fully single-use facility for commercial manufacture can still easily cost \$25-\$40 million.


Despite the biopharma industry's bright future, successful companies in this complex worldwide industry will continue to require complete and accurate knowledge of the market and competing technologies, along with adequate lead-times, large capital expenditures, and careful planning. Biopharmaceutical development and manufacture are very costly, the industry is very competitive, investors increasingly demand higher stock prices and profits, and weak companies and products tend to die, so no company can afford to make tactical or strategic mistakes. This makes accurate market and manufacturing planning all the more essential. The industry needs to keep on top of the current situation and future trends.

This report summarizes survey data and information obtained from biopharmaceutical manufacturers worldwide in late 2015 and early 2016. Its intent is to provide a quantitative-based overview and assessment of industry capacity, production trends, and benchmarks, along with presenting industry views on these and other subjects. As an on-going benchmarking effort, this study offers a view into current and future potential global industry problems and opportunities.

1-4 BIOPHARMACEUTICAL R&D PIPELINES

Figure 1.1 shows survey respondent responses concerning the indications of the biopharmaceutical products their companies are working on. Cancer and infectious diseases continue to dominate the biopharmaceutical development pipeline. Trials have increased with most indications. Cancer treatment remains by far the most active area, with over 4,000 products now in development.

Fig 1.1: Investigational Drugs: Large Molecule (Protein Therapeutics), Worldwide, 2010 - 2015



Source: BioPharm Insight, www.infinata.com/biopharma-solution/by-product/biopharm-insight.html, February 2015

Note: Biopharm Insight includes multiple counts for the same therapeutic, when in multiple phases and locations of clinical trials. Therefore, the total counts will be higher than the actual number of drugs and relevant trials.




A trend in recent years has been a major increase in the number and percentage of monoclonal antibodies in clinical trials. This can be expected to further increase, as the key ‘Cabilly’ patents broadly covering most conventional recombinant monoclonal antibody manufacture, held by Genentech/Roche, expire in the U.S. in 2018; as blockbuster and other monoclonal antibody-related patents expire and; related to this, as a large number of biosimilar antibodies enter the market. An increasing portion of cancer therapeutics involve recombinant monoclonal antibodies or antibody fragments, further indicating that the number and percentage of marketed monoclonal antibodies will increase in coming years. And we may finally see antibody fragments and other microbially-manufactured antibody-like agents start to substantially supplement or even displace traditional mammalian antibody manufacture.

Figure 1.2 shows the breakout of the cumulative pipeline for large molecule biologics in various stages of development and launched (on the market). Typically, less than 10% of the total numbers of products that enter clinical development actually make it to the marketplace.


Fig 1.2: Worldwide Pipeline & Launched Products, Large Molecules, January 2015

(Note: Cumulative Worldwide Pipeline, Large Molecules, Having Attained Various Stages of Development)



Source: BioPharm Insight, www.infinata.com/biopharma-solution/by-product/biopharm-insight.html January 2015



Fig 1.3: Current Worldwide Pipeline & Launched Products, Large Molecules, January 2015

Source: BioPharm Insight, www.infinata.com/biopharma-solution/by-product/biopharm-insight.html, January 2015



1-5 BIOSIMILARS IN THE PIPELINE

There is a very healthy pipeline of follow-on (biosimilar and biobetter) products in development targeted for the U.S., EU and other major markets (see www.biosimilarpipeline.com).


Biosimilars are further discussed in more detail in another section below. This pipeline includes nearly 800 biosimilars, about ≥ 600 of these presumed targeted to major markets, and about 500 biobetters in development, a total of about 1,400 follow-on biopharmaceutical products in the development pipeline for over 100 currently-marketed biopharmaceuticals (see www.biosimilarpipeline.com). While biosimilars are finally starting to substantially penetrate the market in the European Union, in the U.S., despite approval of 2 biosimilars, including an antibody, in 2015, FDA is still moving at a glacial pace – only approving its first product about 5 full years after passage of BPCIA legislation enable FDA approval of biosimilars. FDA still has not yet issued many needed guidelines. Basic issues affecting biosimilars future markets, such as product names (nomenclature) and interchangeability, have yet to be resolved, with these among many issues making planning biosimilar development and marketing very difficult. At least the initial guidance and approvals from FDA are reassuring, in the sense that they contain few surprises and are unlikely to disrupt ongoing development activities.

Most biosimilars/biobetters are being manufactured using current vs. the generally decades-old legacy technology and equipment being used for most reference product manufacture. Biosimilars will include products pioneering new expression systems and other bioprocessing technologies. Ultimately, many of these products could well be significantly better in some or many respects, including safety and efficacy, such as having higher purity, than their usually several decades-old legacy reference products. If too different, including two better, this

would negate biosimilar approval (with full approval required). Many biosimilar developers are using CMOs for development and manufacturing services. Major CMOs report recent revenue increases of 15% attributable to biosimilar contracts.


Fig 1.4 below shows the number of U.S.-marketed reference products by the years of their biosimilar versions' launchability in the U.S. Ability to launch requires both relevant patents and regulatory-granted market exclusivities, essentially orphan status and 12-year new exclusivity granted to all new full BLAs, be expired upon product launch. Note, in the U.S., there are large numbers of biosimilars likely to enter the market in the next few years, with another large group, including many blockbuster monoclonal antibodies, likely entering the market late in the decade.

Fig 1.4: Number of Reference Products by U.S. Biosimilars Launchable Dates



The projected economic impact of biosimilars/ biobetters, from a U.S.-centric perspective is portrayed in Fig 1.5. This shows the magnitude of cumulative current reference product sales by the year of likely biosimilars for these products first entering the U.S. market (i.e., expiration of all patent and market exclusivities.) With patents expiring on the majority of currently marketed biopharmaceuticals, including most recombinant proteins and mAbs, these products with current cumulative annual revenue of about \$100 billion will encounter much new competition in the U.S. (and other major markets) from biosimilars (and biobetters) starting in just a few years.


Fig 1.5: Biosimilars Launchable Dates by Sum of Current Reference Products Sales (\$millions)



1-6 BIOPHARMACEUTICAL APPROVALS GENERIC

FDA approvals of biopharmaceutical products by year are shown in Figure 1.6.

Fig 1.6: FDA Approvals of New Biopharmaceutical Products 1982-2015



2015 was a record year for FDA biopharmaceutical approvals, including a record number of recombinant protein/mAb approvals. The spike of approvals is, likely, reflecting the increased number and percentage of biopharmaceuticals in the development pipeline. It remains to be seen in coming years whether this is part of trend for increasing FDA biopharmaceutical approvals.

Table 1.1 lists biopharmaceutical products approved (in rev. chron. order) by FDA in 2015.

Table 1.1: Biopharmaceutical Approvals Generic, 2015

insulin glargine rDNA [Basaglar; Abasria; LY2963016]	granted on 12/16/2015 to Boehringer Ingelheim for treatment of diabetes; Note, a 505(b)(2) drug approval, which many would now call a biosimilar
Factor X blood-derived [Coagadex; Coagulation Factor X (Human)]	granted on 12/16/2015 to Bio Products Laboratory Ltd. for treatment of for hereditary Factor X deficiency
von Willebrand factor rDNA [Vonvendi]	granted on 12/9/2015 to Baxalta U.S. (formerly Baxter) for treatment of von Willebrand's disease (VWD)
lysosomal acid lipase [Kanuma; sebelipase alfa]	chicken egg-expressed granted on 12/8/2015 to Alexion (from acquisition of Synageva) for treatment of lysosomal acid lipase (LAL) deficiency [2nd product from genetically engineered animals]
Influenza vaccine quadrivalent [Fluad; influenza vaccine, inactivated, egg-cultured, quadrivalent with MF59/squalene adjuvant]	granted on 12/3/2015 to Novartis (with product and its approval to be transferred to Seqirus, part of CSL Group) for prevention of influenza; first U.S. non-aluminum-based adjuvanted influenza vaccine
SLAMF7 mAb rDNA [Empliciti; elotuzumab; Signaling Lymphocyte Activation Molecule Family member 7 monoclonal antibody, recombinant]	granted on 11/30/2015 to Bristol Myers Squibb (BMS; with Abbvie) for use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received 1-3 prior therapies
EGFr mAb rDNA [Portrazza - necitumumab; epidermal growth factor receptor monoclonal antibody]	granted on 11/24/2015 to Janssen Biotech for treatment of metastatic squamous non-small cell lung cancer(VWD) in combination with gemcitabine and cisplatin
CD38 mAb rDNA [Darzalex - daratumumab]	granted on 11/16/2015 to Eli Lilly for treatment of multiple myeloma
Factor VIII rDNA, pegylated [Adynovate - BAX 111]	granted on 11/11/2015 to Baxalta (formerly Baxter) for treatment of hemophilia A
IL-5 mAb rDNA [Nucala; mepolizumab]	granted on 11/4/2015 to GlaxoSmithKline (GSK) for treatment of asthma
HSV-1/GM-CSF rDNA [Imlygic - alimogene laherpaprevac; a live herpes simplex virus type 1 (HSV-1) oncolytic virus resulting in expression of GM-CSF]	granted on 10/27/2015 to Alexion Pharmaceuticals for treatment of unresectable recurrent cutaneous melanoma
alkaline phosphatase rDNA [Strensiq; asfotase alfa; an alkaline phosphatase catalytic domain fusion protein]	granted on 10/23/2015 to Alexion Pharmaceuticals for treatment of perinatal, infantile and juvenile-onset hypophosphatasia (HPP)
dabigatran mAb rDNA [Praxbind - idarucizumab]	granted on 10/16/2015 to Boehringer Ingelheim to reverse the blood-thinning effects of Pradaxa (dabigatran)
insulin degludec rDNA [Tresiba - insulin degludec]	granted on 10/16/2015 to Novo Nordisk for treatment of diabetes mellitus
insulin degludec/aspart rDNA [Ryzodeg 70/30 - a 70/30 mixture of insulin degludec (approved the same day) and insulin aspart]	granted on 10/16/2015 to Novo Nordisk for treatment of diabetes mellitus
Factor VIII [Nuwiq]	granted on 10/16/2015 to Octapharma USA for treatment of hemophilia A

For Ordering Information on the Full Report, Contact
BioPlan Associates, Inc.
301-921-5979
www.bioplanassociates.com/13th





THIRTEENTH ANNUAL

Report and Survey of Biopharmaceutical Manufacturing Capacity and Production

Another report in the BioPlan Associates, Inc.'s biopharmaceutical series:

- Biosimilars Pipeline Database - <http://www.biosimilarspipeline.com/index.html>
- Top 1000 Global Biomanufacturing Facilities - Global analysis and ranking of capacity, employment and pipelines, www.top1000bio.com
- Biopharmaceutical Expression Systems and Genetic Engineering Technologies
- Advances in Biopharmaceutical Manufacturing and Scale-up Production, 2nd Ed, American Society for Microbiology
- Biopharmaceutical Products in the U.S. and European Markets, 6th Ed
- Advances in Biopharmaceutical Technology in China
- Advances in Biopharmaceutical Technology in India
- Top 60 Biopharmaceutical Organizations in China
- Top 60 Biopharmaceutical Organizations in India
- Quick Guide to Clinical Trials
- Quick Guide to Biotechnology in the Middle East
- Quick Guide to Biofuels

The 13th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production is the most recent study of biotherapeutic developers and contract manufacturing organizations' current and projected future capacity and production. The survey includes responses from 222 responsible individuals at biopharmaceutical manufacturers and contract manufacturing organizations from 27 countries. The survey methodology includes input from an additional 191 direct suppliers of raw materials, services, and equipment to this industry. In addition to current capacity issues, this study covers downstream processing problems, new technologies, expression systems, quality initiatives, human resources and training needs of biopharmaceutical manufacturers, growth rates of suppliers to this industry, and many other areas.

April 2016

ISBN 978-1934-106-28-0

ISBN 9781934106280

